On 22 May 2025, the AI-Mind consortium, joined by the Project Officer and external experts, convened for a pivotal review meeting to assess project progress and plan the final steps ahead of its conclusion in February 2026. Discussions centred on actions to maximise the scientific, clinical and societal impact of AI-Mind in its final phase. This strategic reorientation began in early 2024 with a revision of the consortium’s structure, reflecting a shift in focus from foundational development to the implementation of the AI-Mind solution and ensuring its long-term sustainability. As part of this evolution, DET NORSKE VERITAS® (DNV) officially concluded its involvement on 31 December 2023, having successfully delivered its contributions.
Simultaneously, three new partners: the University of Oslo (UiO), Pre Diagnostics AS and Roche joined the consortium on 1 January 2024, each bringing unique expertise to support AI-Mind’s next phase. As AI-Mind enters its final stretch, its mission remains unchanged: to support early dementia diagnosis and reduce the burden of neurodegenerative diseases across Europe and globally. Now comprising 17 active partners spanning academia, healthcare, and industry, AI-Mind is well-positioned to accelerate the implementation of its cutting-edge dementia risk prediction tools. These tools offer new hope to individuals at risk of mild cognitive impairment (MCI) and dementia.
https://www.ai-mind.eu/blog/a-strategic-reorientation-in-the-consortium-structure/
